Rich has a proven track record in developing business strategies in addition to his expertise in product development and operations
MENLO PARK, CA (PRWEB) January 10, 2006
Aperon Biosystems, a privately-held company focused on the management of asthma, has appointed Richard A. Lotti as its President & Chief Executive Officer. Mr. Lotti brings more than 25 years of operating experience in the medical device industry to Aperon.
"Rich has a proven track record in developing business strategies in addition to his expertise in product development and operations," said Wende Hutton, Venture Partner with Canaan Partners and member of the Board of Directors of Aperon Biosystems. "We are very excited to have Rich join our company to lead the management team at this critical juncture as we prepare to enter the marketplace."
Mr. Lotti is experienced in both venture-capital funded companies and established organizations. Most recently, he was President and CEO of Converge Medical, Inc., a pioneer in less-invasive cardiovascular surgery. Previously, Mr. Lotti was Vice President of Business Development with Cardiothoracic Systems, Inc., the leader in off-pump cardiovascular surgery. While there, he established key strategic alliances and successfully facilitated the sale of the company to Guidant Corporation in 2000. Mr. Lotti also held management positions at Camino Neurocare, Alcon, Pfizer and Johnson & Johnson.
"Aperon is an innovative company with a novel technology that can impact the manner in which asthma is managed and the quality of patient’s lives," Lotti stated. "I look forward to leading this talented organization to demonstrate the clinical effectiveness of the technology and to build awareness among physicians. Aperon is dedicated to establishing this technology as the standard of care for asthma management."
Asthma is a chronic inflammatory disease of the airways in the lungs affecting more than 18 million people in the U.S. Exhaled nitric oxide is a marker for inflammation and provides a means for monitoring the patient's response to anti-inflammatory medications, the mainstay for treatment of symptoms. Clinical research shows that monitoring inflammation on a regular basis to adjust anti-inflammatory medication could significantly improve disease management, resulting in reduced severity of symptoms, fewer exacerbations and optimized drug usage in individual patients.
About Aperon Biosystems
Aperon Biosystems is a privately held company based in Menlo Park, CA. Aperon was founded in 2001 to develop a biosensor platform utilizing a patented Sol-Gel technology for the highly sensitive detection of selected analytes. The first application of this technology is a non-invasive monitor for the measurement of exhaled nitric oxide, suitable for use at physicians’ offices, for the management of asthma. Aperon Biosystems raised $15.3 million in a Series B round of financing in May 2005. Canaan Partners led the round and was joined by Draper Fisher Jurvetson and previous investors, Onset Ventures and Alliance Technology Ventures. For more information, visit the Company’s website at http://www.aperon.com.
Jean M. Nelson
Aperon Biosystems, Inc.
# # #